It might be the latest version of a long-term strategic policy approach, but stakeholders need to ask themselves a critical question. Are they willing to trade a bridging fund and process changes for a few health technologies, based on the promise it could accelerate access, in return for a disinvestment framework and deprioritising most new therapies?
Stakeholders deserve clarity on the strategic objective before this process gets underway
November 25, 2024 Latest NewsBioPharmaCommentLatest Video
New Stories
-
Novartis partners with Advara HeartCare and TerryWhite Chemmart to launch Heart Health Collective,
December 6, 2024 - - Latest News -
Pfizer Australia launches Innovate Reconciliation Action Plan to advance equitable access to health and wellbeing
December 6, 2024 - - BioPharma -
Former CSL CEO Paul Perreault appointed strategic adviser to Microbio
December 5, 2024 - - Latest News -
More evidence backs the use of weight-loss therapies
December 5, 2024 - - Latest News -
ChatGPT would have produced more human responses than these committees
December 5, 2024 - - Latest News -
Anatara provides irritable bowel syndrome clinical trial update
December 4, 2024 - - Australian Biotech -
Digital health company Adherium secures R&D loan facility
December 4, 2024 - - Australian Biotech